PL2638915T3 - Medyczne zastosowanie zmiatacza wolnych rodników i antyoksydantu alfa-1-mikroglobuliny - Google Patents

Medyczne zastosowanie zmiatacza wolnych rodników i antyoksydantu alfa-1-mikroglobuliny

Info

Publication number
PL2638915T3
PL2638915T3 PL13172049T PL13172049T PL2638915T3 PL 2638915 T3 PL2638915 T3 PL 2638915T3 PL 13172049 T PL13172049 T PL 13172049T PL 13172049 T PL13172049 T PL 13172049T PL 2638915 T3 PL2638915 T3 PL 2638915T3
Authority
PL
Poland
Prior art keywords
microglobulin
medical use
radical scavenger
antioxidant alpha
antioxidant
Prior art date
Application number
PL13172049T
Other languages
English (en)
Inventor
Bo Akerström
Stefan Hansson
Martin Lennarth Olsson
Magnus Gram
Original Assignee
A1M Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A1M Pharma Ab filed Critical A1M Pharma Ab
Publication of PL2638915T3 publication Critical patent/PL2638915T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
PL13172049T 2008-07-18 2009-07-17 Medyczne zastosowanie zmiatacza wolnych rodników i antyoksydantu alfa-1-mikroglobuliny PL2638915T3 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US13533808P 2008-07-18 2008-07-18
DKPA200801024 2008-07-18
US18938108P 2008-08-18 2008-08-18
DKPA200801116 2008-08-18
US19750608P 2008-10-27 2008-10-27
DKPA200801478 2008-10-27
EP13172049.2A EP2638915B1 (en) 2008-07-18 2009-07-17 Medical use of the radical scavenger and antioxidant alpha-1-microglobulin

Publications (1)

Publication Number Publication Date
PL2638915T3 true PL2638915T3 (pl) 2017-04-28

Family

ID=41550762

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13172049T PL2638915T3 (pl) 2008-07-18 2009-07-17 Medyczne zastosowanie zmiatacza wolnych rodników i antyoksydantu alfa-1-mikroglobuliny
PL09777272T PL2313106T3 (pl) 2008-07-18 2009-07-17 Medyczne zastosowanie zmiatacza wolnych rodników i antyoksydantu alfa-1-mikroglobuliny

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL09777272T PL2313106T3 (pl) 2008-07-18 2009-07-17 Medyczne zastosowanie zmiatacza wolnych rodników i antyoksydantu alfa-1-mikroglobuliny

Country Status (12)

Country Link
US (1) US10350268B2 (pl)
EP (2) EP2313106B1 (pl)
JP (3) JP5694928B2 (pl)
AU (1) AU2009270435B2 (pl)
CA (1) CA2730531A1 (pl)
DK (2) DK2313106T3 (pl)
ES (2) ES2614490T3 (pl)
HR (2) HRP20160760T1 (pl)
HU (2) HUE030274T2 (pl)
PL (2) PL2638915T3 (pl)
PT (1) PT2638915T (pl)
WO (1) WO2010006809A2 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2544816A1 (en) 2003-11-08 2005-05-26 Prothera Biologics, Llc Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
EP2613150A1 (en) 2007-02-12 2013-07-10 A1M Pharma AB Diagnosis and treatment of preeclampsia
PT2291654T (pt) 2008-05-28 2018-06-15 Prothera Biologics Inc Preparação e composição de proteínas inibidoras de interalfa do sangue
NZ629621A (en) * 2012-09-05 2015-09-25 A1M Pharma Ab Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
CA2885604A1 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of ischemia using inter-alpha inhibitor proteins
WO2015095553A1 (en) * 2013-12-20 2015-06-25 Nephrogenesis, Llc Methods and apparatus for kidney dialysis
EA039776B1 (ru) * 2016-03-18 2022-03-11 Гард Терапьютикс Интернэшнл Айби Новые белки, полученные из альфа-1-микроглобулина, и их применение
WO2018094023A2 (en) * 2016-11-16 2018-05-24 Anand Prasad Cyclic dipeptides and wound healing
AU2018360281A1 (en) 2017-11-03 2020-05-28 Guard Therapeutics International AB Use of alpha-1-microglobulin for protection of bone marrow cells
JP6906807B2 (ja) 2018-08-31 2021-07-21 一般社団法人クラインシュタイン医工学パースペクティブ 透析装置

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166133A (en) * 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
US6103691A (en) * 1994-03-23 2000-08-15 Tschesche; Harald Utilisation of angiogenin and/or α1 -microglobulin and/or complement factor D in order to inhibit the secretion of proteins
US5910482A (en) 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
JP2001348342A (ja) 2001-04-12 2001-12-18 Nippon Zoki Pharmaceut Co Ltd 免疫調整・抗炎症剤
DE10125883A1 (de) 2001-05-28 2002-12-12 Serumwerk Bernburg Ag Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Nierenersatztherapie
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20070060512A1 (en) * 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
AR045074A1 (es) 2003-07-23 2005-10-12 Applied Research Systems Uso de cd164 soluble en desordenes inflamatorios y autoinmunes
ITMI20032528A1 (it) * 2003-12-19 2005-06-20 Francesco Santangelo Uso di cistina o di cisteina per la prevenzione e il
US20060105419A1 (en) 2004-08-16 2006-05-18 Biosite, Inc. Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
JP2007001922A (ja) 2005-06-23 2007-01-11 Asahi Kasei Pharma Kk 透析患者における腎疾患改善剤、又は機能性食品
US20070292421A1 (en) 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
US20080133141A1 (en) 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
EP2613150A1 (en) * 2007-02-12 2013-07-10 A1M Pharma AB Diagnosis and treatment of preeclampsia

Also Published As

Publication number Publication date
PT2638915T (pt) 2017-01-10
WO2010006809A2 (en) 2010-01-21
JP6406987B2 (ja) 2018-10-17
HUE030274T2 (en) 2017-05-29
AU2009270435A1 (en) 2010-01-21
HRP20160760T1 (hr) 2016-08-12
CA2730531A1 (en) 2010-01-21
AU2009270435B2 (en) 2014-10-16
HUE027953T2 (en) 2017-01-30
EP2638915B1 (en) 2016-10-19
HRP20161808T1 (hr) 2017-02-24
JP2016102125A (ja) 2016-06-02
WO2010006809A3 (en) 2010-05-27
JP2015071620A (ja) 2015-04-16
ES2571956T3 (es) 2016-05-27
US10350268B2 (en) 2019-07-16
EP2638915A1 (en) 2013-09-18
DK2313106T3 (en) 2016-07-25
PL2313106T3 (pl) 2016-08-31
EP2313106A2 (en) 2011-04-27
JP5694928B2 (ja) 2015-04-01
JP2012505154A (ja) 2012-03-01
JP6175478B2 (ja) 2017-08-02
ES2614490T3 (es) 2017-05-31
EP2313106B1 (en) 2016-03-30
DK2638915T3 (en) 2017-01-30
US20110190208A1 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
HRP20160760T1 (hr) Medicinska uporaba čistača radikala i antioksidacijskog alfa-1-mikroglobulina
EP2361089A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE
IL216582A0 (en) Composition for use in decreasing the transmission of human pathogens, devices comprising the same and uses thereof
IL209781A0 (en) Novel immunoadjuvant flagellin-based compounds and use thereof
HRP20160902T1 (hr) Pripravci i postupci uporabe forbolskih estera
PL2307391T3 (pl) Tiadiazolilooksyfenyloamidyny i ich zastosowanie jako środki grzybobójcze
HK1185368A1 (en) Heat-curable polyorganosiloxane composition and use thereof
IL216768A0 (en) Aminopyrrolidinone derivatives compositions comprising the same and uses thereof
EP2511333A4 (en) RUBBER COMPOSITION AND USES THEREOF
PL2307390T3 (pl) Tiadiazolilooksyfenyloamidyny i ich zastosowanie jako środki grzybobójcze
GB0718446D0 (en) Compositions and methods for the treatment of infection
EP2267071A4 (en) RUBBER COMPOSITION AND USE THEREOF
EP2345629A4 (en) FLUORESCENT CONNECTION AND ITS USE FOR MEDICAL PURPOSES
HK1188712A1 (en) Films and compositions comprising the same
IL211204A0 (en) Mucoadherents compositions and their use
EP2433996A4 (en) LIQUID COMPOSITION AND ENDOSCOPE
IL225793A0 (en) Methods and preparations for curing insulin-related medical conditions
EP2249789A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF XEROSOMY
EP2261284A4 (en) RUBBER COMPOSITION AND USE THEREOF
EP2285398A4 (en) METHOD AND COMPOSITIONS FOR TREATING ADIPOSITAS
HK1184779A1 (en) Novel compound and medical use thereof
EP2382011A4 (en) COMPOSITIONS FOR THE TREATMENT OF GLUTEN INTOLERANCE AND THEIR APPLICATIONS
EP2344454A4 (en) ANTIOXIDATION COMPOUNDS AND METHOD FOR THEIR USE
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia
GB0812734D0 (en) MEdical compsoitions and devices